ReleaseWire

GlobalData's clinical trial report, "Glucocorticoid-Induced Osteoporosis Global Clinical Trials Review, H1, 2014" provides data on the Glucocorticoid-Induced Osteoporosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Glucocorticoid-Induced Osteoporosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Glucocorticoid-Induced Osteoporosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Actelion Ltd - Product Pipeline Review - 2014

Pyelonephritis - Pipeline Review, H1 2014

GlobalData estimates the 2013 sales for gout at approximately $989m across the 6MM covered in this report. The acute gout segment of the market will double in size over the forecast period, reaching $337m in 2018 at a CAGR of 15%. The chronic gout market, which encompasses urate-lowering and prophylactic anti-inflammatory therapies, will experience even faster growth at a CAGR of 18.8%, and it will more than double in size, reaching over 1.9 billion in 2018. With the current standard of care for gout already encompassing very successful and cheap treatments, the bar for success in the gout market is quite high. As a result, companies are shifting the focus of their research toward more severe gout cases, trying to address the greatest unmet needs. One of the major drivers of the gout market is the growing number of patients suffering from difficult-to-treat gout, for whom the standard therapies are inappropriate due to the presence of comorbidities, unresponsiveness, or intolerance. Targeting this patient niche is the strongest trend in the research and development (R&D) strategies of the gout players.

GlobalData's clinical trial report, "Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2014" provides data on the Amyotrophic Lateral Sclerosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Amyotrophic Lateral Sclerosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Amyotrophic Lateral Sclerosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

China possesses a fourth population in the world and has one of the largest drug markets round the world. By 2012, sales on the Chinese drug market have reached RMB 926.1billion (about US$147 billion) reported by the «2012: Report of China Pharmaceutical Market» published by Chinese Academy of Social Sciences. It is estimated that it will exceed RMB 1,000 billion by 2013. A series of factors, such as an increasingly ageing population, accelerating growth of urban population as well as expansion of healthcare covering urban and rural, will grow the Chinese drug market with a growth rate over 20 percent per annum in next three years. China is expected to become the second largest drug market in the world by 2015.

Ocular Pain - Pipeline Review, H1 2014

The Musculoskeletal Symptoms Partnering 2009-2014 report provides understanding and access to the musculoskeletal symptoms partnering deals and agreements entered into by the worlds leading healthcare companies.

AIMM Therapeutics B.V. - Product Pipeline Review - 2014

Idiopathic Short Stature - Pipeline Review, H1 2014

New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014

Haemophilus Influenzae Type b Infections - Pipeline Review, H1 2014

Uveal Melanoma - Pipeline Review, H1 2014

Affitech A/S - Product Pipeline Review - 2014

Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Alcoholic Hepatitis - Pipeline Review, H1 2014

Community Acquired Pneumonia - Pipeline Review, H1 2014

Acute Lung Injury - Pipeline Review, H1 2014

Pulmonary Inflammation - Pipeline Review, H1 2014

GlaxoSmithKline plc - Product Pipeline Review - 2014

Thrombotic Thrombocytopenic Purpura - Pipeline Review, H1 2014

Encephalomyelitis - Pipeline Review, H1 2014

Aplastic Anemia - Pipeline Review, H1 2014

Recurrent Malignant Glioma - Pipeline Review, H1 2014